top of page
09.09.2026: Press release alert
We are proud to share that Cellmover AS, together with collaborating company VoxCell, has secured Eurostars funding to advance next-generation cancer immunotherapies.
As announced on VoxCell's own website, the project will combine Cellmover's expertise in intracellular checkpoint-blocking nanobodies with VoxCell's advanced vascularized 3D tumor models. Thus the collaboration seeks to establish a predictive preclinical platform for targeted delivery of nanobody therapeutics to tumor-infiltrating immune cells.
"We are excited to partner with VoxCell on this ambitious project. Combining our complementary technologies will accelerate the development of CM101 and generate critical preclinical data to support its path toward clinical development. VoxCell's platform offers a level of human relevance that has not previously been available for nanobody optimization, and we believe it will meaningfully improve the predictive value of our preclinical program."
- Miriam Aarsund Larsen, CEO
Miria
04.08.2026: Say hello to our new Master student, Rannveig!
We're pleased to welcome Rannveig María Halldórsdóttir to Cellmover as our new Master student through collaboration with Norges teknisk-naturvitenskapelige universitet, NTNU!
Over the coming years, Rannveig will be part of our team, gaining hands-on experience in nanobody therapeutics and the day-to-day dynamics of working in a biotech startup.
At Cellmover, we strongly believe in bridging academia and industry by giving students the opportunity to contribute to cutting-edge research in a translational environment.
We look forward to supporting Rannveig throughout her Master project and following her journey with us!
18.06.2026: Kari-Marie joins as summer intern for the Momentum UiO program
We are excited to welcome Kari-Marie Wedel Jarlsberg to Cellmover as our summer intern! Kari-Marie will contribute to our nanobody production activities while gaining hands-on experience in a biotech startup environment. We look forward to having her on board this summer!
Thank you to Momentum UiO and UiO Growth House for creating opportunities that connect talented students with the startup ecosystem.
10.11.2025: Leadership transition at Cellmover: Miriam Aarsund Larsen appointed as new CEO
Cellmover is pleased to announce that Miriam Aarsund Larsen, previously Chief Scientific Officer, has been appointed as the company’s new Chief Executive Officer.
Former CEO Marit Inngjerdingen will continue to play an active role in the company as Chairman of the Board.
Over the past two years, Miriam has been a driving force in shaping Cellmover’s start-up journey and scientific strategy. Her leadership has been instrumental in advancing the company’s mission to develop next-generation nanobody-based therapies for cancer treatment.
This leadership transition marks an exciting new chapter for Cellmover as the company continues to grow and strengthen its mission of transforming cancer immunotherapy.
01.11.2025: Meet Eline - our new associate scientist
👋 Welcome to the team, Eline Scheie-Ahlgren!
We’re thrilled to have Eline join Cellmover as our new Associate Scientist.
Eline holds a Master’s degree in molecular biology and biochemistry from the University of Oslo, where she tested inhibitors of tumor-promoting factors in pancreatic cancer💊 She recently returned from Paris, where she participated in the international iGEM competition🏆
Eline will be instrumental in driving our nanobody production projects forward — we’re so excited to have her on board!
01.10.2025: Cellmover joins Aleap Incubator
Cellmover is excited to announce that we have joined Aleap, Norway’s leading incubator for health and life science start-ups, located at Oslo Science Park.
Aleap provides an inspiring environment for early-stage companies within biotech, medtech, and health innovation. The incubator offers access to a powerful network of industry experts, experienced mentors, and investors — all dedicated to helping life science ventures scale successfully.
By becoming part of the Aleap community, Cellmover gains access to valuable resources and partnerships that will strengthen our business strategy and accelerate our path toward clinical impact. Aleap’s extensive partner network will provide strategic guidance and expertise across regulatory, intellectual property, business development, and clinical operations.
Becoming part of Aleap marks an important milestone in Cellmover’s growth journey — strengthening our ability to translate groundbreaking science into real-world therapeutic solutions.
01.04.2025: Meet Tirill Marie - our new lab engineer
Say hello to Tirill Marie Trøften, our new Lab Engineer at Cellmover! 👋
Tirill Marie holds a master’s degree in biomedical science and brings valuable experience from working in a GMP-regulated lab. With a strong passion for quality and efficiency, she is dedicated to ensuring that everything in the lab runs smoothly. At Cellmover she will play a key role in delivering reliable and accurate results.
Welcome to the Cellmover team, Tirill Marie! We're excited to have you on board🎉
08.03.2025: Norway’s 50 leading women in tech 2025
Our own CSO Miriam Aarsund Larsen was awarded as one of Norway's leading women in tech 2025! ⭐️⭐️
Today Abelia and ODA-Nettverk released the list of Norway's 50 leading women in tech, with the aim to inspire other women and girls to chose technology as education and career path.
Miriam came to Cellmover full-time in 2024, and has already been key to transform the company to a results-oriented and fast pacing company, aiming to develop next-generation therapeutics for cancer therapy. Miriam is extremely dedicated, hard-working, ambitious, and creative, and sets high standards for herself and the company. Plus you are a wonderful colleague, and a joy to work with.
We are extremely proud today, and also congratulate all other women awarded today with this achievement! 🎉
See the full list here
20.12.2024: Press release alert
01.08.2024: Meet Fredrik - our new senior scientist
Our new addition to the team is Fredrik Gullaksen Johannessen!
Fredrik holds a PhD from the University of Bergen working on proteins related to dopamine synthesis and storage. He has experience from industry as he worked as a scientist in CardiNor AS, focusing on developing diagnostic tests for heart failure biomarkers. Fredrik is responsible for the nanobody- and protein purification pipeline and we are very happy to have him on the team!
01.05.2024: Cellmover joins ShareLab
Cellmover is moving into the vibrant incubator ShareLab at Oslo Science Park🚀
Marit Inngjerdingen, CEO of Cellmover: “We are excited to become a part of the ShareLab family. This marks a milestone for our company. Our ShareLab membership enables us to accelerate our R&D, open new opportunities for collaboration, and strengthen our mission to develop cancer immunotherapies.”
Marius Øgaard, co-founder of ShareLab, commented: “Cellmover’s management team is highly competent and possesses rock-solid experience in both science and business. They also have cutting-edge ideas about curing cancer. As a team launching a new deep tech startup, they’re ‘the Right Stuff’, and we are super happy to have them on board at ShareLab!”
09.04.2024: We are hiring!
🔬 Join the Cellmover Team! Are you passionate about advancing innovative therapies? We're hiring! Apply now to be part of our journey developing novel cancer therapeutics.
Please send an application letter with your CV to: miriam@cellmover.com or apply via Finn.no or LinkedIn:
Click here for more information about the position and how to apply via Finn.no
Click here for more information about the position and how to apply via LinkedIn
Deadline: 30.04.2024
01.03.2024: New webside launch
Check out our new website - find more information about our projects and stay updated on Cellmover news.
04.02.2024: The International Cancer Day
Cellmover was profiled by the Norwegian Research Council in connection with the International Cancer Day:
Visste du at det i Norge er over 316 000 personer som har kreft eller har hatt kreft? Og at før fylte 80 år har rundt 4 av 10 nordmenn fått minst én kreftdiagnose? I dag markeres FNs internasjonale kreftdag.
💙 Fordi det forskes på kreft, overlever 3 av 4 som får kreft i Norge. Det er dobbelt så mange som for 50 år siden.
Vi i Forskningsrådet har i perioden 2017-2022 gitt 1,5 milliarder i finansiering til norske aktører som forsker på kreft. Noen av disse er bedriftene PubGene AS, Cellmover og EXACT Therapeutics. Hør dem fortelle med egne ord hvilken nytteverdi deres forskning har for norske kreftpasienter.
#verdenskreftdag #idekraftverdentrenger #kreftforskning
bottom of page